Global Biopharmaceutical Contract Manufacturing Market - Qualitative and Quan...Aiswariya Chidambaram
This presentation which highlights the key market and technology trends in the global biopharmaceutical contract manufacturing market was delivered as a lecture at the In-Focus Seminar session at CPhI Worldwide 2013 held at Frankfurt, Germany.
The U.S. Biopharmaceutical Industry (2014): Perspectives on Future Growth and...PhRMA
The capability to innovate is fast becoming the most important determinant of economic growth and a nation’s ability to compete and prosper in the 21st century global knowledge-based economy.
The innovative biopharmaceutical industry stands out among high-value knowledge-based industries, including aerospace, automotive, and semiconductors, as a driver for future U.S. economic growth. Aging populations throughout the world and rising purchasing power for medical advances among emerging economies are expected to drive increased demand for prescription medicines in the coming years, providing opportunities to increase production and exports.
This research service provides an in-depth analysis of the global pharmaceutical contract manufacturing market with particular focus on the finished dose formulations such as solid, liquid and semi-solid, and injectable dose formulations. Segment analysis, trends and revenue forecast for the global, U.S. and European regions have been provided in detail. Strategic recommendations for the success of market participants have also been discussed.
COVID-19 Impacts on the Global mRNA Vaccines and Therapeutics Market NarayanSharma67
The “Global mRNA Vaccines and Therapeutics Market” is likely to grow at a CAGR of around 13% during the forecast period, i.e., 2021-26, says MarkNtel Advisors. The market growth essentially attributes to the rising prevalence of infectious and chronic diseases, including HIV, diabetes, cancer, and cardiovascular diseases.
Strategic Analysis of the Indian Pharmaceutical Contract Manufacturing Market...Aiswariya Chidambaram
The Indian Pharmaceutical CMO market has been analyzed and assessed with respect to APIs and finished dose formulations (solids, liquids and injectables). Strategic recommendations for the success of market participants have been provided.
Briefing based on the key findings of my research on the Global Generic Pharmaceuticals Market 2010, covering the developed markets like the U.S, Germany, UK, France, Italy and Spain as well as the emerging markets such as India and China.
Contract manufacturing organizations are in a strategic position to serve as the trusted and experienced providers of the industry's most advanced equipment and manufacturing processes.
Rising costs and increasingly complex technologies have put demand for CMOs at an all-time high. Read on to learn about the factors affecting the CMO market and how to select the CMO that's right for you.
https://www.icqconsultants.com/white_paper/biopharma-contract-manufacturing/
Global Biopharmaceutical Contract Manufacturing Market - Qualitative and Quan...Aiswariya Chidambaram
This presentation which highlights the key market and technology trends in the global biopharmaceutical contract manufacturing market was delivered as a lecture at the In-Focus Seminar session at CPhI Worldwide 2013 held at Frankfurt, Germany.
The U.S. Biopharmaceutical Industry (2014): Perspectives on Future Growth and...PhRMA
The capability to innovate is fast becoming the most important determinant of economic growth and a nation’s ability to compete and prosper in the 21st century global knowledge-based economy.
The innovative biopharmaceutical industry stands out among high-value knowledge-based industries, including aerospace, automotive, and semiconductors, as a driver for future U.S. economic growth. Aging populations throughout the world and rising purchasing power for medical advances among emerging economies are expected to drive increased demand for prescription medicines in the coming years, providing opportunities to increase production and exports.
This research service provides an in-depth analysis of the global pharmaceutical contract manufacturing market with particular focus on the finished dose formulations such as solid, liquid and semi-solid, and injectable dose formulations. Segment analysis, trends and revenue forecast for the global, U.S. and European regions have been provided in detail. Strategic recommendations for the success of market participants have also been discussed.
COVID-19 Impacts on the Global mRNA Vaccines and Therapeutics Market NarayanSharma67
The “Global mRNA Vaccines and Therapeutics Market” is likely to grow at a CAGR of around 13% during the forecast period, i.e., 2021-26, says MarkNtel Advisors. The market growth essentially attributes to the rising prevalence of infectious and chronic diseases, including HIV, diabetes, cancer, and cardiovascular diseases.
Strategic Analysis of the Indian Pharmaceutical Contract Manufacturing Market...Aiswariya Chidambaram
The Indian Pharmaceutical CMO market has been analyzed and assessed with respect to APIs and finished dose formulations (solids, liquids and injectables). Strategic recommendations for the success of market participants have been provided.
Briefing based on the key findings of my research on the Global Generic Pharmaceuticals Market 2010, covering the developed markets like the U.S, Germany, UK, France, Italy and Spain as well as the emerging markets such as India and China.
Contract manufacturing organizations are in a strategic position to serve as the trusted and experienced providers of the industry's most advanced equipment and manufacturing processes.
Rising costs and increasingly complex technologies have put demand for CMOs at an all-time high. Read on to learn about the factors affecting the CMO market and how to select the CMO that's right for you.
https://www.icqconsultants.com/white_paper/biopharma-contract-manufacturing/
Genome Editing Market Analysis By Technology (CRISPR, TALEN, ZFN), By Delivery Method (Ex-vivo, In-vivo), By Application (Animal/Plant Cell Editing), By Service (In-house, Outsourced), By End-use And Segment Forecasts, 2018 - 2025
BIOSIMILARS - Regulation and Market Trends Joseph Pategou
Nowadays patients and physicians can have access to three types of drugs: a originators, a generic or a biosimilar.
Those drugs have different regulatory systems that apply in Europe; moreover the biosimilars regulation is evolving and may change. Regulation is an important factor that can give more confidence to patients and healthcare professionals. As a consequence, biosimilaires will grow.
This is part of the MaRS BioEntrepreneurship series.
Speaker: Lynne Zydowsky, Ph.D., Managing Principal Zydowsky Consultants
* Explore the development of regulated drugs and devices
* Understand where and how value is generated in the pharmaceuticals industry
* Appreciate the interplay between science and business in a biotech company
To download a copy of the audio for this presentation, please go to:
http://www.marsdd.com/bioent/oct16
For the event blog and Q+A, please see:
http://blog.marsdd.com/2006/10/17/bringing-together-art-and-science/
In recent years, the pharmaceutical industry has witnessed increased political interest and attention due to the increased recognition of the economic importance and financial impact of healthcare as a component of national budgets. Biologic drugs (biologics) have attracted the attention of politicians since biologics have moved out of the niche pharmaceutical arena to contribute 17% of global pharmaceutical sales, representing revenues of more than $120bn in 2009. The market for biologics is growing at twice the rate of pharmaceutical drugs, placing significant cost pressures on government, employers, insurers, and patients. Government and insurers are using several strategies to contain costs but must ensure that the financial burden placed on patients does not restrict access to the health care system. Establishing a regulatory pathway for ‘follow-on’ biologics (biosimilars) was therefore felt to be necessary by many stake holders to encourage competition and reduce prices. Many pharmacutical companies both large and small - are expecting their bottom line growth to be driven by biosimilars and are channeling their R&D budgets to compete in what – according to many - is going to be one of the hottest areas in a radically changing global pharmaceutical market.
Regenerative Medicine Industry Outlook 2014Pete Shuster
This is an excellent presentation on companies and products that are making their mark on the Regenerative Medicine Market. The outlook for 2014 is encouraging.
Sharing my learning in dealing with complexity and uncertainty and shed some light on:
(a) Understanding the ‘biosimilar paradox’
(b) Accelerating our “QbD” Journey – focusing on ‘from Generics to Biosimilars’
(c) In preparing this talk, collect my thoughts to help NIPTE consider ways for developing its program on Biosimilars to help the Nation improve assurance of quality with confidence and lower costs
(D) Invite the audience to get to know NIPTE and provide us ways to collaborate with industry
2014 Profile: Biopharmaceutical Research IndustryPhRMA
Biopharmaceutical science is a complex, collaborative, resource-intensive enterprise. It requires a highly skilled workforce, sustained investment, and long-term vision. Critical to its success are policies and regulations that foster innovation and broad access to new medicines. By working together—on the science, the research and the policies—we
can help ensure that medicines live up to patients’ hope for new solutions to our greatest health care challenges.
Merck & co., inc. barclays final 3-10-2015Marcel Brussee
What does Merck's $10B buyback plan say about pharma M&A?
Adding $10 billion to its stock buyback program might mean Merck & Co. ($MRK) wants to keep investors happy as its sales continue to shrink. That would be the typical explanation. But The Wall Street Journal sees a different possibility--one the rest of the industry might want to pay attention to.
Source: http://www.fiercepharma.com/story/what-does-mercks-10b-buyback-plan-say-about-pharma-ma/2015-03-26?utm_campaign=SocialMedia
“Managing the changing biopharma risk equation” is an Economist Intelligence Unit (EIU) report sponsored by MilliporeSigma. This paper explores in detail global pharmaceutical companies’ growth strategies and their plans for managing the associated risks.
Increasing costs and new competitors from growth markets are challenging the industry. The consequences are the obligation to increase efficiency and a growing relocation and concentration process. But what is the benchmark for top performance in manufacturing chemical and pharmaceutical products? The ConMoto project study confirms: a Value oriented Maintenance and Asset Management is the key to sustainably increase production efficiency of the chemical and pharmaceutical industry.
Single Use & Disposable Technology in BiomanufacturingPharma IQ
Single Use & Disposable Technology in Biomanufacturing
Pharma IQ Sector Report & Resources June 2011
Downloadable guide to latest developments in this field
LEARN MORE
https://www.disposablebiomanufacturingonline.com/?&shownewswindow=1&utm_source=PharmaIQ&utm_medium=SMO&mac=PMIQ_Slideshare&utm_campaign=Slideshare&utm_term=pdf
Genome Editing Market Analysis By Technology (CRISPR, TALEN, ZFN), By Delivery Method (Ex-vivo, In-vivo), By Application (Animal/Plant Cell Editing), By Service (In-house, Outsourced), By End-use And Segment Forecasts, 2018 - 2025
BIOSIMILARS - Regulation and Market Trends Joseph Pategou
Nowadays patients and physicians can have access to three types of drugs: a originators, a generic or a biosimilar.
Those drugs have different regulatory systems that apply in Europe; moreover the biosimilars regulation is evolving and may change. Regulation is an important factor that can give more confidence to patients and healthcare professionals. As a consequence, biosimilaires will grow.
This is part of the MaRS BioEntrepreneurship series.
Speaker: Lynne Zydowsky, Ph.D., Managing Principal Zydowsky Consultants
* Explore the development of regulated drugs and devices
* Understand where and how value is generated in the pharmaceuticals industry
* Appreciate the interplay between science and business in a biotech company
To download a copy of the audio for this presentation, please go to:
http://www.marsdd.com/bioent/oct16
For the event blog and Q+A, please see:
http://blog.marsdd.com/2006/10/17/bringing-together-art-and-science/
In recent years, the pharmaceutical industry has witnessed increased political interest and attention due to the increased recognition of the economic importance and financial impact of healthcare as a component of national budgets. Biologic drugs (biologics) have attracted the attention of politicians since biologics have moved out of the niche pharmaceutical arena to contribute 17% of global pharmaceutical sales, representing revenues of more than $120bn in 2009. The market for biologics is growing at twice the rate of pharmaceutical drugs, placing significant cost pressures on government, employers, insurers, and patients. Government and insurers are using several strategies to contain costs but must ensure that the financial burden placed on patients does not restrict access to the health care system. Establishing a regulatory pathway for ‘follow-on’ biologics (biosimilars) was therefore felt to be necessary by many stake holders to encourage competition and reduce prices. Many pharmacutical companies both large and small - are expecting their bottom line growth to be driven by biosimilars and are channeling their R&D budgets to compete in what – according to many - is going to be one of the hottest areas in a radically changing global pharmaceutical market.
Regenerative Medicine Industry Outlook 2014Pete Shuster
This is an excellent presentation on companies and products that are making their mark on the Regenerative Medicine Market. The outlook for 2014 is encouraging.
Sharing my learning in dealing with complexity and uncertainty and shed some light on:
(a) Understanding the ‘biosimilar paradox’
(b) Accelerating our “QbD” Journey – focusing on ‘from Generics to Biosimilars’
(c) In preparing this talk, collect my thoughts to help NIPTE consider ways for developing its program on Biosimilars to help the Nation improve assurance of quality with confidence and lower costs
(D) Invite the audience to get to know NIPTE and provide us ways to collaborate with industry
2014 Profile: Biopharmaceutical Research IndustryPhRMA
Biopharmaceutical science is a complex, collaborative, resource-intensive enterprise. It requires a highly skilled workforce, sustained investment, and long-term vision. Critical to its success are policies and regulations that foster innovation and broad access to new medicines. By working together—on the science, the research and the policies—we
can help ensure that medicines live up to patients’ hope for new solutions to our greatest health care challenges.
Merck & co., inc. barclays final 3-10-2015Marcel Brussee
What does Merck's $10B buyback plan say about pharma M&A?
Adding $10 billion to its stock buyback program might mean Merck & Co. ($MRK) wants to keep investors happy as its sales continue to shrink. That would be the typical explanation. But The Wall Street Journal sees a different possibility--one the rest of the industry might want to pay attention to.
Source: http://www.fiercepharma.com/story/what-does-mercks-10b-buyback-plan-say-about-pharma-ma/2015-03-26?utm_campaign=SocialMedia
“Managing the changing biopharma risk equation” is an Economist Intelligence Unit (EIU) report sponsored by MilliporeSigma. This paper explores in detail global pharmaceutical companies’ growth strategies and their plans for managing the associated risks.
Increasing costs and new competitors from growth markets are challenging the industry. The consequences are the obligation to increase efficiency and a growing relocation and concentration process. But what is the benchmark for top performance in manufacturing chemical and pharmaceutical products? The ConMoto project study confirms: a Value oriented Maintenance and Asset Management is the key to sustainably increase production efficiency of the chemical and pharmaceutical industry.
Single Use & Disposable Technology in BiomanufacturingPharma IQ
Single Use & Disposable Technology in Biomanufacturing
Pharma IQ Sector Report & Resources June 2011
Downloadable guide to latest developments in this field
LEARN MORE
https://www.disposablebiomanufacturingonline.com/?&shownewswindow=1&utm_source=PharmaIQ&utm_medium=SMO&mac=PMIQ_Slideshare&utm_campaign=Slideshare&utm_term=pdf
The global organ-on-a-chip market generated revenue of US$ 23.3 million in 2020 and is expected to reach US$ 116.7 million by 2025 with a CAGR of 38.0% in the forecast period. The organ-on-a-chip market report offers a comprehensive market analysis of the different segments and regions that lets readers make crucial business-related decisions with a wealth of information enclosed in this report. The research report offers both qualitative and quantitative information on the global organ-on-a-chip market. In qualitative terms, the organ-on-a-chip market report provides insights into numerous factors, such as market determinants, value chain analysis, emerging trends, growth opportunity analysis, porters five-force model analysis and macro-economic factors, segment analysis, regional analysis at a granular level. Similarly, in quantitative terms, the report provides historical and forecast market numbers of organ-on-a-chip in various segments such as by Offerings, type, application & end-user at global, regional, and country-level. Also, the report provides a detailed analysis of the market vendors and their product offerings. The report also covers details of the competitive market environment and includes information on the capabilities and competencies of market vendors.
China's chemical market is the world's largest which currently faces production overcapacity, slow growth of local demand, and high competition intensity. In this white paper, Solidiance addresses the questions on how to grow and maintain market position as many emerging competitors are moving up to the value chain through product upgrade, continuous innovation, and business expansion.
The answers are “The New Chemical Era in China” which will come up as the phenomenon resulting from the ability of different chemical companies to create their market identities to gain competitiveness.
This phenomenon is expected to gradually open new opportunities in development of different industry sectors, such as automotive, energy, construction, as well as electrical & electronic (E&E).
Point of care testing market and forecast to 2016 global analysisRenub Research
Renub Research (http://www.renub.com/report/point-of-care-testing-market-and-forecast-to-2016-global-analysis-88) has announced the addition of the "Point of Care Testing Market and Forecast to 2016: Global Analysis" report to its offering
Point of Care Testing Market and Forecast to 2016: Global Analysis - Market Overview
The concept of Point of Care Testing (POCT), also known as bedside, near-patient testing and decentralized testing, relates to tests that are conducted by clinical operators at the site of patient care where immediate medical action is taken on the results. The fact that point of care (POCT) represents a departure from conventional laboratory medicine has created new opportunities in the field of diagnostics industry. Technical advancements over recent years have helped point of care testing (POCT) to grow with double digit CAGR from 2009 to 2011 and evolve into a vital diagnostic tool. It is predicted that point of care testing market will be approximately US$ 25 Billion by 2016.
Blood glucose test controls a lion’s market share of around 70% for the year 2011 and it is expected to continue its dominance till 2016. Rest of all the others point of care tests market share covered in this report are in single digit. Infectious disease testing market is expected to double by 2016 from its market of 2011. As countries are making the healthcare more and more accessible to people, the demand for various point of care testing is keep on rising. The point of care testing market has become an established sector worldwide and will continue to provide vital contribution in in-vitro diagnostics industry.
This 83 page report contains 26 Figures and 12 Tables provides a comprehensive analysis of the emerging point of care tests market segments, including their dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for instrument and consumable suppliers. Renub Research report entitled “Point of Care Testing Market and Forecast to 2016: Global Analysis” report also provides market landscape and market share information in the point of care testing market. The report brings together major merger & acquisition, distribution agreement, licensing deals information in point of care testing market. The report also entails major drivers and challenges of point of care testing market.
10 Point of Care Test Segments Covered in this Report
Blood Glucose Testing, Cardiac Marker Testing, Lipid Panel/Cholesterol Testing, Blood Coagulation Testing, Infectious Disease Testing, Urinalysis Testing, Drug of Abuse Testing, Fecal Occult Blood Testing, Pregnancy & Fertility Testing and Tumor Marker Testing
REPORT HIGHLIGHTS * The global excipients market was at $4.6 billion in 2010 and it is expected to reach at $4.9 billion in 2011. It is further anticipated to increase to $6.7 billion by 2016 at a compound annual growth rate (CAGR) of 6.5%. * The market for organic chemicals was at $4.3 billion approximately in 2010 and it is expected to reach at $4.5 billion in 2011. It is further anticipated to increase to $6.3 billion by 2016 at a compound annual growth rate (CAGR) of 6.6%. * The market for inorganic chemicals was at $248 million approximately in 2010 and it is expected to reach at $268 millions in 2011. It is further anticipated to increase to $350 million by 2016 at a compound annual growth rate (CAGR) of 5.5%.INTRODUCTIONREASON FOR THE STUDYAmong the significant forces that continue to affect the global excipients industry in 2011 are a crisis in the global supply chain, the demands of Quality by Design (QbD), and worries about drug safety. Positive trends include the development of creative ideas in response to the need for new excipients and new levels of cooperation between major players (e.g., Dow and Colorcon). These forces are reshaping the global market for excipients.GOALS AND OBJECTIVESThe primary goals of this technical/market report are to provide a detailed analysis of the current excipients market and a forecast of what the market will look like in 5 years. The specific objectives are (1) identify excipients being used; (2) quantify global market volume; (3) track important developments; (4) analyze the structure of the industry and its driving forces; (5) examine the most active companies and describe how they respond to market demands; and (6) provide data with which the reader can further evaluate the industry.AUDIENCEAs a market and technology summary, this report consolidates a wide range of industrial and technical information that should aid excipient suppliers, chemical companies, drug manufacturers, healthcare regulators, and congressional staffers to stay current with today's market. The report should be of value to companies interested in entering or expanding their involvement in the field. The report should provide senior marketing personnel and executive planners with insight about what materials can best satisfy customer demands. Market projections may be of interest to venture capitalists interested in exploring commercialization opportunities, as well as companies and personnel involved in designing and constructing chemical and excipient manufacturing plants and/or those who service such plants. The report offers useful background to consultants in the field. The report can serve as an introductory resource for newcomers to the business, including new employees. In addition, the report can offer background to governmental officials examining reform. SCOPE OF REPORTExcipients in Pharmaceuticals offers coverage of the most important issues surrounding excipients: technological, regulatory, economic, and political issues, and so on. Excluded from the study are ingredients for cosmetics, personal care, food, quasi-medical, unorthodox, alternative, home remedies, underground and/or illegal drugs, and veterinary drugs.This report organizes information from diverse sources into sections entitled Summary, Overview, Technology, Industry Structure, and Company Profiles. The Summary encapsulates several key conclusions and includes a table of market findings. The Overview provides deep background information on the most important issues of the day, including the global supply chain crisis, QbD, and legislative prospects. The Technology section examines excipients by chemical compounds, functional uses, and delivery systems, and as finished products. The Industry Structure section discusses the market environment, strategies, influences, market shares, international aspects, and other related factors. The Company Profiles segment provides summaries of more than 120 companies that
Health & Insurance - Presentation by Min-Sung Sean Kim, Partner of Allianz Ventures at the NOAH Conference Berlin 2017, Tempodrom on the 23rd of June 2017.
Oligonucleotides are short DNA or RNA molecules and have specific sequence of nucleotide residue, which makes an entire molecule. Oligonucleotides readily bind in specific sequencing manner to their respective DNA-RNA oligonucleotide to form duplex chain.
A Trust-Centric Healthcare Journey | Full Presentation of PharmaLedger's 1st ...PharmaLedger
In this #1 Open Webinar | A trust-centric healthcare journey presentation, you will find:
An introduction to the PharmaLedger project presented by Lynn Wang (Johnson & Johnson)
Topic 1 | Clinical Supply Traceability presented by Francesco Spoto (Novartis) and Chad Sklodosky (Pfizer)
Topic 2 | Finished Goods Traceability presented by Dr Jan Wortmann (Bayer) and Bernhard Salb (Roche)
Topic 3 | ePI – Electronic Product Information presented by Patrick Maher (Novartis) and Ken Thursby (MSD)
Topic 4 | Anti-Counterfeiting presented by Daniel Fritz (Novartis) and Alberto Lòpez (Imprensa Nacional Casa da Moeda)
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
Trailblazing scientists who are the backbone of our industry. These are the people that discover the molecules and develop the medicines to tackle the toughest diseases we face in society.
Mercer Capital's Value Focus: Medical Device Manufacturers | Q1 2014 | Five T...Mercer Capital
Mercer Capital provides medical device manufacturers, related start-up enterprises, and private equity funds with valuation services, including purchase price allocation, 409a compliance, goodwill impairment testing, and other transaction and valuation advisory services.
Each issue includes a segment focus, market overview, mergers and acquisitions review, and more.
5 big bets to drive growth in 2024 without one additional marketing dollar AND how to adapt to the biggest shifting eCommerce trend- AI.
1) Romance Your Customers - Retention
2) ‘Alternative’ Lead Gen - Advocacy
3) The Beautiful Basics - Conversion Rate Optimization
4) Land that Bottom Line - Profitability
5) Roll the Dice - New Business Models
Come learn how YOU can Animate and Illuminate the World with Generative AI's Explosive Power. Come sit in the driver's seat and learn to harness this great technology.
First Things First: Building and Effective Marketing Strategy
Too many companies (and marketers) jump straight into activation planning without formalizing a marketing strategy. It may seem tedious, but analyzing the mindset of your targeted audiences and identifying the messaging points most likely to resonate with them is time well spent. That process is also a great opportunity for marketers to collaborate with sales leaders and account managers on a galvanized go-to-market approach. I’ll walk you through the methods and tools we use with our clients to ensure campaign success.
Key Takeaways:
-Recognize the critical role of strategy in marketing
-Learn our approach for building an actionable, effective marketing strategy
-Receive templates and guides for developing a marketing strategy
Short video marketing has sweeped the nation and is the fastest way to build an online brand on social media in 2024. In this session you will learn:- What is short video marketing- Which platforms work best for your business- Content strategies that are on brand for your business- How to sell organically without paying for ads.
Top 3 Ways to Align Sales and Marketing Teams for Rapid GrowthDemandbase
In this session, Demandbase’s Stephanie Quinn, Sr. Director of Integrated and Digital Marketing, Devin Rosenberg, Director of Sales, and Kevin Rooney, Senior Director of Sales Development will share how sales and marketing shapes their day-to-day and what key areas are needed for true alignment.
Everyone knows the power of stories, but when asked to come up with them, we struggle. Either we second guess ourselves as to the story's relevance, or we just come up blank and can't think of any. Unlocking Everyday Narratives: The Power of Storytelling in Marketing will teach you how to recognize stories in the moment and to recall forgotten moments that your audience needs to hear.
Key Takeaways:
Understand Why Personal Stories Connect Better
How To Remember Forgotten Stories
How To Use Customer Experiences As Stories For Your Brand
It's another new era of digital and marketers are faced with making big bets on their digital strategy. If you are looking at modernizing your tech stack to support your digital evolution, there are a few can't miss (often overlooked) areas that should be part of every conversation. We'll cover setting your vision, avoiding siloes, adding a democratized approach to data strategy, localization, creating critical governance requirements and more. Attendees will walk away with actions they can take into initiatives they are running today and consider for the future.
SMM Cheap - No. 1 SMM panel in the worldsmmpanel567
Boost your social media marketing with our SMM Panel services offering SMM Cheap services! Get cost-effective services for your business and increase followers, likes, and engagement across all social media platforms. Get affordable services perfect for businesses and influencers looking to increase their social proof. See how cheap SMM strategies can help improve your social media presence and be a pro at the social media game.
Videos are more engaging, more memorable, and more popular than any other type of content out there. That’s why it’s estimated that 82% of consumer traffic will come from videos by 2025.
And with videos evolving from landscape to portrait and experts promoting shorter clips, one thing remains constant – our brains LOVE videos.
So is there science behind what makes people absolutely irresistible on camera?
The answer: definitely yes.
In this jam-packed session with Stephanie Garcia, you’ll get your hands on a steal-worthy guide that uncovers the art and science to being irresistible on camera. From body language to words that convert, she’ll show you how to captivate on command so that viewers are excited and ready to take action.
Mastering Local SEO for Service Businesses in the AI Era is tailored specifically for local service providers like plumbers, dentists, and others seeking to dominate their local search landscape. This session delves into leveraging AI advancements to enhance your online visibility and search rankings through the Content Factory model, designed for creating high-impact, SEO-driven content. Discover the Dollar-a-Day advertising strategy, a cost-effective approach to boost your local SEO efforts and attract more customers with minimal investment. Gain practical insights on optimizing your online presence to meet the specific needs of local service seekers, ensuring your business not only appears but stands out in local searches. This concise, action-oriented workshop is your roadmap to navigating the complexities of digital marketing in the AI age, driving more leads, conversions, and ultimately, success for your local service business.
Key Takeaways:
Embrace AI for Local SEO: Learn to harness the power of AI technologies to optimize your website and content for local search. Understand the pivotal role AI plays in analyzing search trends and consumer behavior, enabling you to tailor your SEO strategies to meet the specific demands of your target local audience. Leverage the Content Factory Model: Discover the step-by-step process of creating SEO-optimized content at scale. This approach ensures a steady stream of high-quality content that engages local customers and boosts your search rankings. Get an action guide on implementing this model, complete with templates and scheduling strategies to maintain a consistent online presence. Maximize ROI with Dollar-a-Day Advertising: Dive into the cost-effective Dollar-a-Day advertising strategy that amplifies your visibility in local searches without breaking the bank. Learn how to strategically allocate your budget across platforms to target potential local customers effectively. The session includes an action guide on setting up, monitoring, and optimizing your ad campaigns to ensure maximum impact with minimal investment.
Financial curveballs sent many American families reeling in 2023. Household budgets were squeezed by rising interest rates, surging prices on everyday goods, and a stagnating housing market. Consumers were feeling strapped. That sentiment, however, appears to be waning. The question is, to what extent?
To take the pulse of consumers’ feelings about their financial well-being ahead of a highly anticipated election, ThinkNow conducted a nationally representative quantitative survey. The survey highlights consumers’ hopes and anxieties as we move into 2024. Let's unpack the key findings to gain insights about where we stand.
How to Run Landing Page Tests On and Off Paid Social PlatformsVWO
Join us for an exclusive webinar featuring Mariate, Alexandra and Nima where we will unveil a comprehensive blueprint for crafting a successful paid media strategy focused on landing page testing.With escalating costs in paid advertising, understanding how to maximize each visitor’s experience is crucial for retention and conversion.
This session will dive into the methodologies for executing and analyzing landing page tests within paid social channels, offering a blend of theoretical knowledge and practical insights.
The Pearmill team will guide you through the nuances of setting up and managing landing page experiments on paid social platforms. You will learn about the critical rules to follow, the structure of effective tests, optimal conversion duration and budget allocation.
The session will also cover data analysis techniques and criteria for graduating landing pages.
In the second part of the webinar, Pearmill will explore the use of A/B testing platforms. Discover common pitfalls to avoid in A/B testing and gain insights into analyzing A/B tests results effectively.
The digital marketing industry is changing faster than ever and those who don’t adapt with the times are losing market share. Where should marketers be focusing their efforts? What strategies are the experts seeing get the best results? Get up-to-speed with the latest industry insights, trends and predictions for the future in this panel discussion with some leading digital marketing experts.
How to Use AI to Write a High-Quality Article that Ranksminatamang0021
In the world of content creation, many AI bloggers have drifted away from their original vision, resulting in low-quality articles that search engines overlook. Don't let that happen to you! Join us to discover how to leverage AI tools effectively to craft high-quality content that not only captures your audience's attention but also ranks well on search engines.
Disclaimer: Some of the prompts mentioned here are the examples of Matt Diggity. Please use it as reference and make your own custom prompts.
2. The single-use technology (SUT) market is estimated to more than quadruple in the
coming years, which will pull the need for compatible bioreactors of volume lower
than 2000L
Evolution of Biotechnology & Equipments Markets – 2011 to 2016, est., $ Billions -
2011
2016 est.
300,0
12,5
+107%
+136%
145,0
5,3
2,8
0,6
Biotherapeutics overall
Upstream (bioproduction)
+367%
Total SUT market
0,5
1,3
+160%
R&D-support
single-use systems
Disposables and related market estimates; the good manufacturing practice (GmP) market for single-use technology (SUT) today is estimated at
us $150 million (for plastic tubing, manifolds, and connectors used with stainless steel systems).
For bioreactors, the market is almost equally divided between SIP and SUT. Most of the bioreactors in place have a volume inferior than 2000L.
“There’s been a shift from blockbuster drugs produced in massive quantities to niche-busters, so we’re moving toward smaller volumes at the
same time that titers in bioreactors are getting higher”.
Sources : contractpharma.com
2
3. Disposable Bioreactors have seen a peak of interest in late 2011, as well as a
few months ago
Disposable bioreactors online queries – 2004-2013, % of maximum search volume -
Sources : Google Trends
3
4. The SUT still have many limitations which limit their implementation in the
pharmaceutical industries
Manufacturing disposable equipment having high-quality/high-tech control systems at the same time is a big
challenge, since these manufacturing processes need different core competencies.
Single-use sensors still have a lack of performance and, therefore, sometimes do not meet the needs for highperformance process control. Also finding materials free from leachables/extractables is still a challenge.
Manufacture single-use bioreactors that encompass microbial culture with, for example, high oxygen demand or a
larger pH range is a challenge. The limits here are clearly the higher requirements for material stability and higher
performance sensors, similar to nondisposable solutions.
Customers need to be open to redeveloping and optimizing their processes to the technology, which will result in
an increased overall yield.
Single-use bioreactors are relatively expensive and have to be handled correctly to avoid damage. Construction of
the bags requires mechanical welding of the seams and this needs to be of the highest quality in order to ensure
that welds do not come apart and result in lost sterility and consequently loss of the entire run.
The complete lack of standardization renders the implementation of SUT, or any change in the production process
more complex than necessary.
Customers are asking for more detailed characterization of films, raw materials, and other plastic components with
the goal of better assessing the patient risk associated with production single-use bioreactors.
Sources : genengnews.com
4
5. Substituting products are rare, however new competitors could emerge
Risks for GPC activity:
“Virtual R&D”.
Mutualization of R&D by CMOs growing larger.
Integration of bioreactor design and production in pharmaceutial companies / CMOs.
Low required investment to enter the market
5
6. The pharmaceutical market undergoes a financial transition which renders
the development of new therapeutics even riskier than in the past
„The cost of developing an asset has remained relatively static while the likely revenues have declined. The
cost of developing an aset, from discovery to launch, has increades slightly by four per cent from $1,089
milion to $1,137 in 2012. Average inflow per asset is forcast to decline by 14% relative to 2010 to reach a
figure of $2,166 million in 2012.“
Sources : Deloitte Life Science innovation Report
6
7. Only 5 out of the 12 biggest pharmaceutical companies have enough
molecules in the pipeline to stay financially healthy in 2017
Drug pipeline & associated estimated revenues– 2012-2017est, # of drugs, Bn€ Number of drugs in development
Incremental revenues from new pipeline 2012-2017
EU companies
EU companies
EU
comp.
7,5 Bn€
7,3 Bn€
12,0 Bn€
7,4 Bn€
6,5 Bn€
5,3 Bn€
4,1 Bn€
8
21
Johnson Novo
&
Nordisk
Johnson
3,2 Bn€
53
56
65
3,0 Bn€
28
35
37
3,0 Bn€
Bayer
Novartis
Merk
Eli Lilly
Sources : Businessweek
60
Astra- Bristolzeneca Meyers
67
80
90
5,3 Bn€
3,0 Bn€
Pfizer
Sanofi
Roche GlaxoSmithKline
7
8. The number of clinical trials is still growing, but might reach a peak despite
efforts made by goverments to facilitate drug devlopment
Evolution of number of clinical trials – Thousands of clinical trials, 2000-2012 Registered studies (thousands)
Y-to-Y Growth
138,8
+52%
119,4
101,3
+30%
+27%
+19%
+19%
+16%
+26%
83,5
66,4
+15%
+18%
+21%
+15%
+14%
2011
2012
49,3
35,9
25,0
5,6
7,0
8,6
10,3
12,1
2000
2001
2002
2003
2004
Sources : clinicaltrials.gov
2005
2006
2007
2008
2009
2010
8
9. The market share of biopharmaceuticals is growing but is controlled by only
a few key companies
Evolution of the Pharmaceutical Market
– Billion USD, 2001-2011 -
Biopharmaceutical Global Production Capacity
– Share of production capacity, 2011 -
Biopharmaceuticals
Rest of Pharma
855
812
770
727
684
641
489
38
(8%)
451
523
46
(9%)
477
560
51
(9%)
509
599
59
(10%)
69
(11%)
82
(12%)
95
(13%)
106
(14%)
117
(14%)
128
(15%)
889
139
(16%)
Others
Roche
21%
25%
Novartis 5%
540
572
602
632
664
695
727
750
Eli Lilly 5%
Sanofi
9% Johnson
& Johnson
6%
9%
6%
Pfizer
7%
Lonza
8%
Boehringer
Ingelheim
Amgen
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Sources : GiResearch
9
10. The top CMOs are based in Germany, Switzerland and the USA, and have
made a growth of 9,9 % between 2011 and 2012
Top 10 CMO ranking– Million USD, # of Employees, 2012-
10
11. Of the top 27 european companies by R&D investment, 6 are Pharmaceutical
companies, and account for 23% of the total investment in 2010.
Top 27 European Investors in R&D– Billion Euros, 2011 Volkswagen
Nokia
Daimler
Sanofi-Aventis
GlaxoSmithKline
Siemens
Robert Bosch
Bayer
AstraZeneca
EADS
Ericsson
BMW
Alcatel-Lucent
Boehringer Ingelheim
Peugeot (PSA)
Finmeccanica
Fiat
Volvo
SAP
Renault
Philips Electronics
STMicroelectronics
Continental
BASF
Merck DE
Banco Santander
Novo Nordisk
3,21
3,20
3,08
3,02
2,77
2,56
2,45
2,40
1,97
1,94
1,80
1,73
1,73
1,70
1,63
1,53
1,41
1,40
1,34
1,27
4,94
4,85
4,39
4,38
4,24
3,82
Sources : The 2011 EU Industrial R&D Investment Scoreboard
6,26
In the pharmaceutical sector, the top
3 countries investing in R&D are :
United Kingdom
France
Germany
11
12. Although the number of approvals is similar in Europe and in the U.S.A.,
France is less and less involved in new drug development
The Food and Drug Administration (FDA) approved the same number of new drugs in 2010 and 2011 as the
Medecines Agency (EMA), +/-1. However, France is less and less chosen by the EMA as reviewer in
centralized procedures.
Also, only 7% of AMM filing belonged to France in 2010 vs. 14% in 2009.
Sources : LEEM
12
13. There is a cyclical tendency that might reflect the intensive financial needs of
the pharmaceutical industry
Filings of NME/NBE and approvals by the FDA– # of filings & approals, 1993-2012 NME/NBE filings
NME/NBE approvals by the FDA
53
50
45
41
43
39
36 35
28
29
25 26
36
30
21
35
24
30
26
22
26
21
17
36
34
32
30
26 27
39
38
20
24
22
26
22 21
18
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Sources : FDA Filling and approval file Allyprime
13